Form D · Biotechnology
Mitokinin, Inc.
New York, NY · CIK 0001717169
Offering snapshot reported Nov 16, 2018 · SEC filing
- Reported sold
- $5M Offering amount: $6M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 17, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 16, 2018 | Initial | $5,000,000 | No comparison | 3 | SEC filing |
| Sep 18, 2017 | Initial | $4,532,198 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-326016
Source: Form D, filed Nov 16, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Doug Crawford | Director |
| Douglas Crawford | Director |
| Daniel De Roulet, Jr. | Director, Executive |
| Johannes Fruehauf | Director |
| Nicholas Hertz | Director |
| Peter Parker | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
45 Broadway, Suite 1440
New York, NY, 10006
New York, NY, 10006